Fresh Autologous Whole Blood Transfusion After Cardiopulmonary Bypass

Description

Autologous blood transfused at the end of cardiopulmonary bypass will reduce total blood loss 24 hours after surgery and improve mitochondrial oxygen delivery measured by plasma succinate levels. The study design is a prospective randomized interventional trial of transfusion of fresh autologous whole blood versus standard of care expectant management of bleeding during elective cardiac surgery.

Conditions

Cardiac Disease, Bleeding Postoperative

Talk to us

Study Overview

On this page

Study Details

Study overview

Autologous blood transfused at the end of cardiopulmonary bypass will reduce total blood loss 24 hours after surgery and improve mitochondrial oxygen delivery measured by plasma succinate levels. The study design is a prospective randomized interventional trial of transfusion of fresh autologous whole blood versus standard of care expectant management of bleeding during elective cardiac surgery.

Targeted Fresh Autologous Whole Blood Transfusion After Cardiopulmonary Bypass: a Prospective Randomized Controlled Trial.

Fresh Autologous Whole Blood Transfusion After Cardiopulmonary Bypass

Condition
Cardiac Disease
Intervention / Treatment

-

Contacts and Locations

Aurora

University of Colorado Hospital, Aurora, Colorado, United States, 80045

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Adult subjects aged 18 to 90
  • 2. Able to provide informed consent
  • 3. Willing to accept autologous or allogenic blood transfusion
  • 4. Scheduled for elective cardiac surgery with cardiopulmonary bypass
  • 1. Pre-operative administration of allogenic blood bank products in the previous 3 months
  • 2. Hemodynamically unstable defined as a systolic blood pressure less than 90 mmHg with a heart rate greater 100 or requiring intravenous vasopressor medications
  • 3. Significant active infection or sepsis defined by positive blood culture or positive wound culture
  • 4. Hemoglobin less than 7 g/dl

Ages Eligible for Study

18 Years to 90 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Colorado, Denver,

Nathan Clendenen, M.D., PRINCIPAL_INVESTIGATOR, University of Colorado - School of Medicine

Study Record Dates

2026-09